Cancer Vaccine Development
Killing malignant not normal B cells important for vaccine development
Published in Vaccine Weekly, October 20th, 2004
According to recent research from the United States, "A major limitation of idiotype vaccination is the requirement for patient-specific reagents. This could be overcome using shared framework region peptides."
"Knowing that this does not lead to loss of normal B-cell responses is important in bringing this approach to clinical trials," wrote John G. Gribben at the Dana Farber Cancer Institute.
The researchers concluded: "This could be overcome using shared framework region peptides. Knowing that this does not lead to loss of normal B-cell responses is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-10-20)
More Articles from Vaccine Weekly
- AIDS/HIV Vaccine
Site mapping in HIV genome may provide new approach to vaccine design - Anthrax Vaccine
DNA vaccine protects mice against challenge anthrax STI spores - Hypertension Vaccine
Vaccine elicits anti-angiotensin I antibodies in hypertensive subjects - Microencapsulation
Microspheres induce adult-like CD8+ cytotoxic T cell responses - Prostate Cancer Vaccine
Antigen-derived peptides induce CTLs in prostate cancer patients - AIDS/HIV Vaccine
HLA class I serotypes important in vaccine efficacy assessments - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
